Cannabinoids for Pain Control During Medical Abortion
- 7 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 135 (6) , 1289-1295
Abstract
OBJECTIVE: To evaluate whether prophylactic dronabinol, a synthetic tetrahydrocannabinol, reduces pain during medical abortion. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of women undergoing medical abortion with mifepristone and misoprostol up through 70 days of gestation. All participants received 800 mg of ibuprofen and were randomized to either 5 mg of oral dronabinol or a placebo 30 minutes before misoprostol administration. Participants used a text messaging service to report pain on a numeric rating scale from 0 to 10 (0=no pain, 10=worst pain). The primary outcome was maximum pain experienced during the 24 hours after misoprostol administration. Secondary outcomes were pain scores at 0, 6, and 24 hours after misoprostol administration; maximum anxiety and nausea scores; use of additional pain medication; reported side effects; and satisfaction (yes or no). We needed 68 participants (34 per group) to have 80% power to detect a 2-point difference in maximum pain on a numeric rating scale. RESULTS: From November 2018 to May 2019, we randomized 70 women (dronabinol=35, placebo=35). Participants in the study arms had comparable baseline characteristics. We found no difference between groups in the median maximum pain score reported (dronabinol 7 [interquartile range 6–8], placebo 7 [interquartile range 5–8], P=.82) or median pain scores at any timepoint. Groups were also no different in mean maximum anxiety (dronabinol 3.33 [SD 3.06], placebo 3.23 [SD 2.53], P=.88) or nausea scores (dronabinol 2.21 [SD 2.32], placebo 2.72 [SD 2.64], P=.41). Most women were satisfied with their pain management (76% dronabinol, 82% placebo, P=.51). CONCLUSION: Dronabinol does not reduce the maximum level of pain experienced by women undergoing medical abortion. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03604341.Keywords
This publication has 21 references indexed in Scilit:
- Cannabinoids for Medical UseJAMA, 2015
- Geographic Variation in Opioid Prescribing in the U.S.The Journal of Pain, 2012
- Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostolContraception, 2009
- Cannabinoids in the management of difficult to treat painTherapeutics and Clinical Risk Management, 2008
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative painThe Journal of Pain, 2003
- Clinically Important Changes in Acute Pain Outcome MeasuresJournal of Pain and Symptom Management, 2003
- Timing of pain and bleeding after mifepristone-induced abortionContraception, 2000
- Potential Interventions for HIV/AIDS Wasting: An OverviewJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trialBJOG: An International Journal of Obstetrics & Gynaecology, 2000